TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Theriva Biologics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.20−0.00 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $9.39M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -274.0% | 681.8% | – | |
| Return on assets | -102.2% | -78.3% | – | |
| Current ratio | 1.09 | 2.67 | 1.74 | |
| Interest coverage | – | – | -394.3× | |
| Diluted shares | 0M | 0M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Theriva Biologics generated $84.57M from operations and spent $656.00K on capital expenditure, dividends and share buybacks. 56% of that went back into the business.
Generated
$84.57M
Used
$656.00K
Capital expenditure$368.00K56%Dividends$00%Share buybacks$288.00K44%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$16.67M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$16.67M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.15 → 1.74
- No dilutionShare count did not rise1M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –